AccuStem (OTCQB:ACUT) Sciences Inc CEO Wendy Blosser joined Steve Darling from Proactive to share more details about the company that started as a spinout of Tiziana Life Sciences to focus on three primary healthcare verticals including pharmaceuticals, diagnostics or devices. The company’s main product is StemPrintER which is a 20-gene test using stem cells to predict cancer recurrence.
Blosser telling Proactive more about the technology and where they see as the biggest opportunities. One of those is a recent announcement that saw the company agree to a joint clinical collaboration agreement with University Hospitals.
She says that agreement will provide tissue samples with clinical outcomes to AccuStem (OTCQB:ACUT) for research purposes. The agreement covers different cancers but will initially focus on breast cancer.